Receptor-directed Therapy of T-cell Leukemias and Lymphomas

Overview

Journal J Immunotoxicol

Publisher Informa Healthcare

Specialties Allergy & Immunology
Environmental Health
Toxicology

Date 2008 Jun 24

PMID 18569395

Citations 6

Authors

John C Morris

Thomas A Waldmann

John E Janik

Affiliations

Soon will be listed here.

Abstract

T-Cell leukemias and lymphomas represent a less common and heterogeneous group of lymphoid neoplasms. Overall, they respond less well to chemotherapy and have a poorer prognosis than their B-cell counterparts. T-Cell tumors express a number of potential targets for receptor-directed antibody therapy; however, there is no available therapeutic monoclonal antibody for these diseases with comparable activity to that of rituximab in B-cell disorders. Despite this, alemtuzumab, a humanized anti-CD52 monoclonal antibody has demonstrated meaningful anti-tumor activity in a variety of T-cell malignancies. A number of other antibodies, modified antibodies and immunotoxins directed against targets such as CD2, CD4, CD5, CD25, CD30 and CD122 expressed on malignant T-cells are under investigation. The current status of receptor-directed antibody therapy for T-cell leukemia and lymphoma is reviewed.

Citing Articles

Intratumoral anti-HuD immunotoxin therapy for small cell lung cancer and neuroblastoma.

Ehrlich D, Wang B, Lu W, Dowling P, Yuan R J Hematol Oncol. 2014; 7:91.

PMID: 25523825 PMC: 4293823. DOI: 10.1186/s13045-014-0091-3.

Characteristics of CARMA1-BCL10-MALT1-A20-NF-κB expression in T cell-acute lymphocytic leukemia.

Ma Y, Liao Z, Xu Y, Zhong Z, Wang X, Zhang F Eur J Med Res. 2014; 19:62.

PMID: 25384343 PMC: 4228272. DOI: 10.1186/s40001-014-0062-8.

Markedly additive antitumor activity with the combination of a selective survivin suppressant YM155 and alemtuzumab in adult T-cell leukemia.

Chen J, Pise-Masison C, Shih J, Morris J, Janik J, Conlon K Blood. 2013; 121(11):2029-37.

PMID: 23321252 PMC: 3596962. DOI: 10.1182/blood-2012-05-427773.

Mutations increased overexpression of Notch1 in T-cell acute lymphoblastic leukemia.

Lin C, Zheng H, Wang C, Yang L, Chen S, Li B Cancer Cell Int. 2012; 12:13.

PMID: 22480166 PMC: 3347979. DOI: 10.1186/1475-2867-12-13.

Analysis of the expression pattern of the BCL11B gene and its relatives in patients with T-cell acute lymphoblastic leukemia.

Huang X, Chen S, Shen Q, Yang L, Li B, Zhong L J Hematol Oncol. 2010; 3(1):44.

PMID: 21080944 PMC: 2992472. DOI: 10.1186/1756-8722-3-44.

References

Zhang Z, Zhang M, Ravetch J, Goldman C, Waldmann T . Effective therapy for a murine model of adult T-cell leukemia with the humanized anti-CD2 monoclonal antibody, MEDI-507. Blood. 2003; 102(1):284-8. DOI: 10.1182/blood-2002-11-3601. View

Lonberg N . Human antibodies from transgenic animals. Nat Biotechnol. 2005; 23(9):1117-25. DOI: 10.1038/nbt1135. View

Nashan B, LIGHT S, Hardie I, Lin A, Johnson J . Reduction of acute renal allograft rejection by daclizumab. Daclizumab Double Therapy Study Group. Transplantation. 1999; 67(1):110-5. DOI: 10.1097/00007890-199901150-00019. View

Olsen N, Brooks R, Cush J, Lipsky P, St Clair E, Matteson E . A double-blind, placebo-controlled study of anti-CD5 immunoconjugate in patients with rheumatoid arthritis. The Xoma RA Investigator Group. Arthritis Rheum. 1996; 39(7):1102-8. DOI: 10.1002/art.1780390705. View

Kim Y, Duvic M, Obitz E, Gniadecki R, Iversen L, Osterborg A . Clinical efficacy of zanolimumab (HuMax-CD4): two phase 2 studies in refractory cutaneous T-cell lymphoma. Blood. 2007; 109(11):4655-62. DOI: 10.1182/blood-2006-12-062877. View

Dobbeling U, Dummer R, Laine E, Potoczna N, Qin J, Burg G . Interleukin-15 is an autocrine/paracrine viability factor for cutaneous T-cell lymphoma cells. Blood. 1998; 92(1):252-8. View

Queen C, SCHNEIDER W, Selick H, Payne P, Landolfi N, DUNCAN J . A humanized antibody that binds to the interleukin 2 receptor. Proc Natl Acad Sci U S A. 1989; 86(24):10029-33. PMC: 298637. DOI: 10.1073/pnas.86.24.10029. View

Medeiros L, Elenitoba-Johnson K . Anaplastic Large Cell Lymphoma. Am J Clin Pathol. 2007; 127(5):707-22. DOI: 10.1309/r2q9ccuvtlrycf3h. View

Gallamini A, Zaja F, Patti C, Billio A, Specchia M, Tucci A . Alemtuzumab (Campath-1H) and CHOP chemotherapy as first-line treatment of peripheral T-cell lymphoma: results of a GITIL (Gruppo Italiano Terapie Innovative nei Linfomi) prospective multicenter trial. Blood. 2007; 110(7):2316-23. DOI: 10.1182/blood-2007-02-074641. View

10.

Branco L, Barren P, Mao S, Pfarr D, Kaplan R, Postema C . Selective deletion of antigen-specific, activated T cells by a humanized MAB to CD2 (MEDI-507) is mediated by NK cells. Transplantation. 1999; 68(10):1588-96. DOI: 10.1097/00007890-199911270-00026. View

11.

Knop S, Hebart H, Gratwohl A, Kliem C, Faul C, Holler E . Treatment of steroid-resistant acute GVHD with OKT3 and high-dose steroids results in better disease control and lower incidence of infectious complications when compared to high-dose steroids alone: a randomized multicenter trial by the EBMT.... Leukemia. 2007; 21(8):1830-3. DOI: 10.1038/sj.leu.2404731. View

12.

Sanchez-Madrid F, Davignon D, Martz E, Springer T . Antigens involved in mouse cytolytic T-lymphocyte (CTL)-mediated killing: functional screening and topographic relationship. Cell Immunol. 1982; 73(1):1-11. DOI: 10.1016/0008-8749(82)90431-2. View

13.

Waldmann T . The structure, function, and expression of interleukin-2 receptors on normal and malignant lymphocytes. Science. 1986; 232(4751):727-32. DOI: 10.1126/science.3008337. View

14.

Marti R, Pujol R, Servitje O, Palou J, Romagosa V, Bordes R . Sézary syndrome and related variants of classic cutaneous T-cell lymphoma. A descriptive and prognostic clinicopathologic study of 29 cases. Leuk Lymphoma. 2003; 44(1):59-69. DOI: 10.1080/1042819021000054652. View

15.

Hale G, Bright S, Chumbley G, Hoang T, Metcalf D, Munro A . Removal of T cells from bone marrow for transplantation: a monoclonal antilymphocyte antibody that fixes human complement. Blood. 1983; 62(4):873-82. View

16.

Kanegane H, Tosato G . Activation of naive and memory T cells by interleukin-15. Blood. 1996; 88(1):230-5. View

17.

Skov L, Kragballe K, Zachariae C, Obitz E, Holm E, Jemec G . HuMax-CD4: a fully human monoclonal anti-CD4 antibody for the treatment of psoriasis vulgaris. Arch Dermatol. 2003; 139(11):1433-9. DOI: 10.1001/archderm.139.11.1433. View

18.

Treumann A, Lifely M, Schneider P, Ferguson M . Primary structure of CD52. J Biol Chem. 1995; 270(11):6088-99. DOI: 10.1074/jbc.270.11.6088. View

19.

STEIN H, Foss H, Durkop H, Marafioti T, Delsol G, Pulford K . CD30(+) anaplastic large cell lymphoma: a review of its histopathologic, genetic, and clinical features. Blood. 2000; 96(12):3681-95. View

20.

Ohno T, Yamaguchi M, Oka K, Miwa H, Kita K, Shirakawa S . Frequent expression of CD3 epsilon in CD3 (Leu 4)-negative nasal T-cell lymphomas. Leukemia. 1995; 9(1):44-52. View